Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.
No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Various factors block sufferers of disease from receiving treatment that is effective and has widespread availability. Sickle cell patients are missing out on…
If Marx had a gay, 'highly educated' brother
Daniel Cressy, 23, says path leading to completion of curative gene therapy is his 'greatest blessing'A young south-eastern Louisiana man recently became the f…
Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, a…
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE